IL146232A0 - Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders - Google Patents

Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders

Info

Publication number
IL146232A0
IL146232A0 IL14623200A IL14623200A IL146232A0 IL 146232 A0 IL146232 A0 IL 146232A0 IL 14623200 A IL14623200 A IL 14623200A IL 14623200 A IL14623200 A IL 14623200A IL 146232 A0 IL146232 A0 IL 146232A0
Authority
IL
Israel
Prior art keywords
dopamine
receptor ligands
treating kidney
kidney disorders
producing medicaments
Prior art date
Application number
IL14623200A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL146232A0 publication Critical patent/IL146232A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14623200A 1999-05-07 2000-04-28 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders IL146232A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
IL146232A0 true IL146232A0 (en) 2002-07-25

Family

ID=7908194

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14623200A IL146232A0 (en) 1999-05-07 2000-04-28 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
IL146232A IL146232A (en) 1999-05-07 2001-10-30 Use of dopamine D3 receptor ligands to produce drugs to treat kidney disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146232A IL146232A (en) 1999-05-07 2001-10-30 Use of dopamine D3 receptor ligands to produce drugs to treat kidney disease

Country Status (19)

Country Link
US (2) US7098214B1 (ja)
EP (1) EP1176963B1 (ja)
JP (3) JP4727822B2 (ja)
KR (2) KR20010112474A (ja)
CN (2) CN101524356A (ja)
AT (1) ATE284693T1 (ja)
AU (1) AU770671B2 (ja)
BR (1) BR0010337A (ja)
CA (1) CA2368823C (ja)
CZ (1) CZ301832B6 (ja)
DE (2) DE19922443A1 (ja)
DK (1) DK1176963T3 (ja)
ES (1) ES2234597T3 (ja)
HU (1) HU228516B1 (ja)
IL (2) IL146232A0 (ja)
NO (1) NO329325B1 (ja)
PT (1) PT1176963E (ja)
WO (1) WO2000067847A2 (ja)
ZA (1) ZA200110044B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
AU7989400A (en) * 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
ATE313534T1 (de) 2001-02-16 2006-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
CA2438318A1 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
EP1392676B1 (en) * 2001-02-16 2006-12-13 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP2005508841A (ja) * 2001-03-29 2005-04-07 スミスクライン・ビーチャム・コーポレイション 化合物および方法
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
DE602004014261D1 (de) * 2003-03-17 2008-07-17 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
JP4904267B2 (ja) * 2004-08-09 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物
AU2005293693B2 (en) 2004-10-14 2011-11-17 AbbVie Deutschland GmbH & Co. KG 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006040179A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
KR101315192B1 (ko) 2004-10-14 2013-10-10 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체 조절에 반응하는 질환 치료에 적합한헤테로사이클릭 화합물
ES2436178T3 (es) 2004-10-14 2013-12-27 Abbvie Deutschland Gmbh & Co Kg Compuestos aromáticos sustituidos con arilsulfonilmetilo o arilsulfonamida adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
KR20090035581A (ko) * 2006-08-04 2009-04-09 아지노모토 가부시키가이샤 신장 기능 장해 예방ㆍ치료제
JPWO2009093471A1 (ja) * 2008-01-25 2011-05-26 学校法人日本大学 アポトーシス抑制薬
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (ja) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
AU4559100A (en) 2000-11-21
ZA200110044B (en) 2003-03-06
CN1360502B (zh) 2010-08-04
NO20015413L (no) 2001-11-15
ATE284693T1 (de) 2005-01-15
CA2368823A1 (en) 2000-11-16
HUP0202399A2 (hu) 2002-12-28
NO329325B1 (no) 2010-09-27
JP2011088941A (ja) 2011-05-06
US20060223793A1 (en) 2006-10-05
US8785447B2 (en) 2014-07-22
DK1176963T3 (da) 2005-04-25
PT1176963E (pt) 2005-05-31
JP5542713B2 (ja) 2014-07-09
ES2234597T3 (es) 2005-07-01
DE19922443A1 (de) 2000-11-09
KR100781828B1 (ko) 2007-12-03
HUP0202399A3 (en) 2003-02-28
IL146232A (en) 2007-06-03
KR20070040425A (ko) 2007-04-16
WO2000067847A2 (de) 2000-11-16
KR20010112474A (ko) 2001-12-20
JP2002544178A (ja) 2002-12-24
JP5897054B2 (ja) 2016-03-30
CN1360502A (zh) 2002-07-24
DE50008964D1 (de) 2005-01-20
EP1176963A2 (de) 2002-02-06
AU770671B2 (en) 2004-02-26
CZ301832B6 (cs) 2010-07-07
WO2000067847A3 (de) 2001-08-02
NO20015413D0 (no) 2001-11-06
CZ20014015A3 (cs) 2002-02-13
CN101524356A (zh) 2009-09-09
US7098214B1 (en) 2006-08-29
BR0010337A (pt) 2002-02-13
JP4727822B2 (ja) 2011-07-20
HU228516B1 (en) 2013-03-28
JP2014098044A (ja) 2014-05-29
EP1176963B1 (de) 2004-12-15
CA2368823C (en) 2008-10-21

Similar Documents

Publication Publication Date Title
IL146232A0 (en) Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
BG108495A (en) 5-ht receptor ligands and uses thereof
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
WO1999017755A3 (en) Medicaments
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
EP1149078A4 (en) 5-HT 6 RECEPTOR LIGANDS? SELECTIVE
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
GB9716879D0 (en) Treatment of attention deficit disorders
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
AU2002358469A1 (en) Modified receptors for the discovery of therapeutic ligands
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
WO2004022542A3 (de) Substituierte 1,2,3,4-tetrahydrochinolinderivate
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
WO2003059352A3 (fr) Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.

Legal Events

Date Code Title Description
HP Change in proprietorship
FF Patent granted
KB Patent renewed